Create a narrative

BioCryst Pharmaceuticals Community

NasdaqGS:BCRX Community

1 Narratives written by author
0 Comments on narratives written by author
21 Fair Values set on narratives written by author

Create a narrative

BioCryst Pharmaceuticals

AN

AnalystConsensusTarget

Consensus Narrative from 12 Analysts

ORLADEYO Pipeline Will Deliver New Therapeutic Opportunities

Key Takeaways ORLADEYO's revenue growth, patient conversion, and reduced royalty payments enhance profitability, cash flow, and financial stability for BioCryst Pharmaceuticals. Advancements in diverse clinical pipelines and new NDAs could significantly diversify future revenue and boost high-margin therapeutic offerings.

US$16.58

FV

39.9% undervalued

17.22%

Revenue growth p.a.

0

0

0

2 days ago